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Background: The vascular endothelial growth factor receptor (VEGFR) pathway plays a pivotal role in solid malignancies and is
probably involved in chemotherapy resistance. Pazopanib, inhibitor of, among other receptors, VEGFR1–3, has activity as single
agent and is attractive to enhance anti-tumour activity of chemotherapy. We conducted a dose-finding and pharmacokinetic (PK)/
pharmacodynamics study of pazopanib combined with two different schedules of ifosfamide.
Methods: In a 3þ 3þ 3 design, patients with advanced solid tumours received escalating doses of oral pazopanib combined with
ifosfamide either given 3 days continuously or given 3-h bolus infusion daily for 3 days (9 gm 2 per cycle, every 3 weeks).
Pharmacokinetic data of ifosfamide and pazopanib were obtained. Plasma levels of placental-derived growth factor (PlGF),
vascular endothelial growth factor-A (VEGF-A), soluble VEGFR2 (sVEGFR2) and circulating endothelial cells were monitored as
biomarkers.
Results: Sixty-one patients were included. Pazopanib with continuous ifosfamide infusion appeared to be safe up to 1000mg per
day, while combination with bolus infusion ifosfamide turned out to be too toxic based on a variety of adverse events. Ifosfamide-
dependent decline in pazopanib exposure was observed. Increases in PlGF and VEGF-A with concurrent decline in sVEGFR2
levels, consistent with pazopanib-mediated VEGFR2 inhibition, were observed after addition of ifosfamide.
Conclusion: Continuous as opposed to bolus infusion ifosfamide can safely be combined with pazopanib. Ifosfamide
co-administration results in lower exposure to pazopanib, not hindering biological effects of pazopanib. Recommended dose of
pazopanib for further studies combined with 3 days continuous ifosfamide (9 gm 2 per cycle, every 3 weeks) is 800mg daily.
Given the heterogeneity of cancer, it is conceivable that combina-
tions of anti-tumour agents render the best outcomes for patients
with advanced solid malignancies.
The combination of conventional cytotoxic therapy with
inhibition of the vascular endothelial growth factor receptor
(VEGFR) pathway is attractive for several reasons. The VEGFR
inhibition reduces the interstitial pressure of tumours rendering
higher intratumoural levels of concomitantly administered cyto-
toxic agents and enhances effects of several cytotoxic agents at the
tumour cell level (Boucher and Jain, 1992; Heldin et al, 2004;
Willett et al, 2004). In addition, most VEGFR-inhibiting agents
have no overlapping toxicities with conventional cytotoxics.
Pazopanib is a tyrosine kinase inhibitor targeting the VEGFR1-3,
the platelet-derived growth factor receptors a and b and c-kit
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(Hamberg et al, 2010a). It received marketing approval for patients
with metastatic renal cell carcinoma and for patients with
advanced non-adipocytic soft tissue sarcomas (Sternberg et al,
2010; Van der Graaf et al, 2012). The recommended dose of
pazopanib is 800mg once daily with fatigue, diarrhoea, nausea,
hypertension and elevated liver-enzymes as most common
toxicities (Van der Graaf et al, 2012).
Ifosfamide is standard of care for different tumour types
including advanced soft tissue sarcomas, where a continuous
and bolus infusion schedule have shown equivalent activity
(Lorigan et al, 2007). Myelosuppression, febrile neutropenia
(FN) and encephalopathy are the most relevant toxicities
(Lorigan et al, 2007).
Given the potential of the combination of pazopanib and
ifosfamide, we performed a phase I study to determine the
recommended dose of pazopanib combined with ifosfamide in two
different schedules.
PATIENT AND METHODS
Patient selection. Patients with advanced or metastatic solid
tumours for whom ifosfamide-based therapy was considered
appropriate or for whom no standard therapy was available were
eligible. Other inclusion criteria included: ECOG performance
status o2, evaluable or measurable disease (RECIST 1.1)
(Eisenhauer et al, 2009), age X18 years, adequate bone marrow,
liver, and renal function, and systolic blood pressure (BP)
o160mmHg and diastolic BPo90mmHg (two antihypertensive
drugs allowed). Main exclusion criteria were: history of cardiovas-
cular disease other than hypertension and signs/symptoms of
central nervous system metastases.
The study was approved by the institutional review boards and
conducted in accordance with the principles embodied in the
Declaration of Helsinki. Written informed consent was obtained
from each participant prior to enrollment.
Study design. Daily oral pazopanib was evaluated in combination
with a fixed dose of ifosfamide 9 gm 2 per cycle, either given as 3
days continuous intravenous infusion (CIV) or as 3 h bolus
intravenous infusion (BIV) for 3 consecutive days, both at 3-weekly
intervals. Pazopanib was escalated in serial cohorts at a dose of 400,
800 and 1000mg daily. If the maximal tolerated dose (MTD)
would be exceeded at 400mg then an extra cohort exploring
pazopanib at 200mg daily was added.
The 3þ 3þ 3 design, a novel model recently proposed aiming
to reduce falsely halting dose escalation in combination phase I
trials, was applied in the original protocol (Hamberg et al, 2010b).
If a dose-limiting toxicity (DLT) was observed in one patient, three
additional patients were recruited at that dose level, with dose
escalation proceeding if no further DLT occurred at that dose level.
If DLT was observed in two out of six, three additional patients
were enrolled. If a DLT occurred in 2 out of 3,42 out of 6 or42
out of 9 patients in a cohort, MTD had been exceeded. The MTD
was defined as the highest dose level with a DLT incidence
of o33%.
In order to be exposed to steady-state concentrations
of pazopanib and to determine the effects of ifosfamide
administration on pazopanib pharmacokinetics (PK), patients in
the dose-escalation phase started on pazopanib 7 days prior to the
first cycle of ifosfamide. At the MTD, six additional patients were
treated in an expansion cohort to get better insight into the safety
profile, to confirm the MTD, and to further study the PK
interaction. For the latter, pazopanib was started 7 days after the
first ifosfamide cycle in the patients in the expansion phase, which
enabled an intra-patient comparison of ifosfamide PK with or
without the presence of pazopanib (Figure 1).
Using the Common Terminology Criteria for adverse events,
version 3.0, DLT during the first treatment cycle (in the dose
expansion phase during the first two treatment cycles) was defined
as: grade 4 neutropenia X7 days, FN, grade 4 thrombocytopenia,
creatinine clearancep50mlmin 1, grade 3–4 proteinuria or any
drug-related grade 3 or 4 non-haematological toxicity. Hyperten-
sion was considered DLT in case of symptomatic hypertension;
persistent (424 h) and asymptomatic systolic BP 4170mmHg
and/or diastolic BP 4100mmHg; systolic BP 160-170 and/or
diastolic BP 90-100 that could not be controlled within 2 weeks; or
an increase of diastolic BP 420mmHg, which despite
antihypertensive medication was not adequately controlled within
2 weeks. A dose delay or interruption exceeding 2 weeks was
classified as DLT. If neutropenia comprised the predominant DLT
at a certain dose level, that and subsequent levels were explored in
combination with granulocyte cell stimulating factor (pegfilgrastim
6mg once per cycle).
Patients were treated for a maximum of six ifosfamide cycles.
Patients experiencing clinical benefit from the combination of
pazopanib and ifosfamide were allowed to continue treatment
thereafter with pazopanib until disease progression or unacceptable
toxicity.
PK sampling and analysis. Concentrations of ifosfamide
and its most important metabolites, 2-dechloroethyl-ifosfamide,
3-dechloroethyl-ifosfamide and 4-hydroxy-ifosfamide were quan-
titated as previously reported in 11–16 samples per ifosfamide
cycle (Hamberg et al, 2010c).
For the analysis of pazopanib, 15 samples per patient
were drawn and quantitated as previously reported (Hurwitz
et al, 2009).
Statistical data analysis. Plasma concentrations of ifosfamide and
its metabolites were plotted as a function of time. Area under the
curve (AUC) was calculated by the trapezoidal method. Non-
compartmental PK analysis including half-life (T½, h) was
calculated using the software package WinNonlin version 6.1.
Total body clearance of ifosfamide was calculated by dividing the
administered dose by the AUC of ifosfamide. Statistical analysis
were made using the software package SPSS (v20). Correlation of
the changes in AUC or clearance and half-life was evaluated by a
two-sided paired t-test for subjects in the expansion cohorts.
Median plasma pazopanib concentration-time profiles were
generated for subjects in the dose escalation cohorts. The area
under the plasma pazopanib concentration–time curve from 0 to
24 h (AUC (0–24)) was calculated using nominal blood sample
collection times after administration of pazopanib on day 21 cycle
1 (pazopanib alone) and day 3 cycle 2 (pazopanib plus ifosfamide)
for subjects in the expansion cohorts.
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Figure 1. Study design. Abbreviation: Ifos¼ ifosfamide.
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Biomarker analysis. Biomarker samples were collected in all
patients at baseline and prior cycle 2 day 1. During the escalation
phase, an additional sample was drawn prior to day 1 cycle 1 and
during the expansion prior to the first pazopanib dose. Circulating
endothelial cell (CEC) enumeration was determined with a
flow-cytometry-based method (Kraan et al, 2012). Plasma
concentrations of VEGF-A, soluble VEGFR2 (sVEGFR2) and
placental-derived growth factor (PlGF) were determined using
ELISA (R&D Systems, Minneapolis, MN, USA) according to the
manufacturers’ instructions.
RESULTS
Dose escalation, MTD and dose intensity. In total, 61 patients
were enrolled (Table 1), 29 in the CIV schedule and 32 on the BIV
schedule. In all, 15 out of 61 patients were not evaluable for
determination of DLT of the combination and were replaced. The
most common reason was early progression (n¼ 5). Two other
patients were registered but did not receive a dose of study
drug at all. Three patients appeared not to tolerate the single agent
treatment they received before the second agent was added. As the
aim of this study was to identify the MTD of the combination of
pazopanib and ifosfamide, it was decided to replace these patients.
Five others were not evaluable due to a diversity of reasons
including withdrawal of consent (not based on toxicity), and an
allergic reaction to mesna, which was prophylactically adminis-
tered with ifosfamide.
In the CIV arm, no DLTs were observed in the three evaluable
patients at the first dose level, whereas 1 DLT (FN) was observed at
a dose level with 800mg pazopanib (six evaluable patients). At the
highest pre-defined dose level of 1000mg pazopanib two DLTs
occurred (FN and encephalopathy) in nine patients. During
expansion phase (n¼ 6) at this dose level, no additional DLTs
were observed. At the MTD in the CIV arm, the dose intensity of
ifosfamide and pazopanib was 92% and 93%, respectively, with a
median number of ifosfamide cycles of 4.
In the first two patients treated with 400mg pazopanib in the
BIV arm, an episode of FN was encountered. Adding G-CSF to the
400mg pazopanib dose level three DLTs were observed in nine
patients (grade 3 encephalopathy, grade 3 proteinuria and grade 3
pneumonia during neutropenia). The dose of pazopanib was de-
escalated to 200mg and supported with G-CSF. In two out of the
first nine evaluable patients DLTs occurred (one case each of grade
3 encephalopathy and FN). The subsequent dose expansion in
another six patients resulted in three more DLTs (pneumonia
during neutropenia and grade 5 cardiac arrest in one patient, renal
toxicity and grade 3 fatigue).
Toxicity. In addition to hematological toxicity, the main
grades 3–4 toxicities during combination therapy were fatigue
and hypophosphatemia, irrespective of treatment schedule. Grade
3–4 vomiting was more pronounced in the BIV-treated patients,
whereas all grades of hypertension and grade 3/4 neutropenia
occurred more often in the CIV group. (Table 2)
Pharmacokinetics. Pazopanib had no impact on plasma half-life,
AUC or clearance, of ifosfamide or any of its metabolites. Figures 2
and 3 depicts the ifosfamide concentrations with and without
concomitant administration of pazopanib.
In contrast, pazopanib concentrations declined byB35% within
72 h during concomitant ifosfamide infusion in patients in the
dose escalation phase during CIV (Figure 4). There seems to be a
time-dependent effect, resulting in comparable median plasma
pazopanib concentrations at the end of ifosfamide infusion across
dose-levels of pazopanib (Figure 4).
PK analysis in patients treated in the dose expansion phase
revealed that the mean AUC (0–24) of pazopanib was reduced by
B27% upon co-administration of ifosfamide as compared with the
AUC of pazopanib single agent (Figure 5).
Biomarker analysis. During the treatment with pazopanib, there
was a dose-dependent increase in PlGF and VEGF-A with a
concurrent decline in sVEGFR2 (Table 3). Importantly, this
phenomenon remained intact after the addition of ifosfamide.
No consistent pattern was seen by enumeration of CEC (data
not shown).
Anti-tumour activity. Of 45 patients evaluable for response,
10 partial responses were observed: 4 in the CIV-treated patients
(2 patients with synovial sarcoma, 1 each with ovarian and prostate
cancer) and 6 patients in the BIV schedule (urothelial cancer
(n¼ 2), one each with sarcoma not otherwise specified, mesothe-
lioma, ovarian cancer and an cancer of unknown primary).
Prolonged disease stabilisation defined as stable disease for at least
3 months was noted in nine and five patients in the CIV and BIV
group, respectively.
DISCUSSION
In this study, we explored safety and tolerability of the
combination of pazopanib and ifosfamide, and its possible
dependence on the ifosfamide infusion schedule. Pazopanib in
combination with BIV-administered ifosfamide turned out to be
intolerable. In contrast, if ifosfamide is continuously administered
over 3 days, pazopanib could be escalated to dose levels exceeding
the registered single agent dose of 800mg daily. The inclusion of a
dose higher than the registered single agent dose was done, since in
a previous study a drug–drug interaction between ifosfamide and
sunitinib resulted in a decreased exposure to sunitinib (Hamberg
Table 1. Demographics and baseline characteristics
Age (median, years) 56 (range 18–76)
Gender
Male 40 (65)
Female 21 (35)
WHO
0 23 (38)
1 38 (62)
Tumour type
Sarcoma (incl GIST) 19
Melanoma 6
Urothelial carcinoma 6
Ovarian carcinoma 5
Carcinoma of unknown primary 5
Prostate 4
Gastric carcinoma 3
Oesophageal carcinoma 3
Miscellaneous 10
Previous non-hormonal systemic anticancer treatment
0 12
1 29
2 11
3 3
4 4
5 1
Abbreviation: GIST¼gastro-intestinal stromal tumour.
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et al, 2010c). This observation was confirmed in the current study,
showing a PK interaction between pazopanib and ifosfamide.
Our study clearly underlines that the administration schedule of
one of the drugs of a combination can have a major impact on the
tolerability of the combination. One of the reasons that could
account for the observed differences in tolerability between the two
schedules of ifosfamide might be a schedule-dependent drug–
drug interaction. Previously, pazopanib has demonstrated PK
interactions with conventional chemotherapy, resulting in higher
exposure to paclitaxel or the combination of paclitaxel
and carboplatin (Tan et al, 2010; Burris et al, 2012; Du Bois
et al, 2012). In contrast, combining pazopanib with full-dose
gemcitabine was feasible up to 800mg pazopanib and no PK
Table 2. Most frequent adverse events during the first and during all combination cycles
CIV (n¼26) BIV (n¼27)
First cycle adverse
events
Adverse events at all
combination cycles
First cycle adverse
events
Adverse events at all
combination cycles
Grade 3/4 All grades Grade 3/4 All grades Grade 3/4 All grades Grade 3/4 All grades
Anaemia 1 21 5 26 0 23 4 27
Thrombocytopaenia 1 7 3 13 3 14 5 17
Neutropaenia 23 24 25 25 13 16 15 19
Fatigue 2 24 6 25 2 20 5 23
Nausea 1 24 2 25 2 22 2 23
Vomiting 0 15 0 21 5 20 6 21
Mucositis 0 8 0 11 0 4 0 8
Anorexia 0 17 0 22 1 15 4 18
Constipation 0 17 0 19 0 13 0 15
Diarrhoea 0 10 0 15 1 7 1 11
Hypertension 1 10 2 13 1 3 2 4
Encepahlopathy 1 10 1 14 2 9 3 14
ALAT 0 13 0 19 0 11 1 12
ASAT 0 14 1 19 0 12 0 16
Hypophosphatemia 2 11 5 13 1 12 5 17
Proteinuria 1 11 1 12 0 9 0 15
Abbreviations: ALAT¼ alanine aminotransaminase; ASAT¼ aspartate aminotransferase; BIV¼bolus intravenous infusion; CIV¼ continuous intravenous infusion.
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Figure 2. Mean concentrations (plus s.d.) of ifosfamide administered
alone (closed symbols: bars up) or in combination with pazopanib
(open symbols, bars down) during the 3 days continuous infusions.
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Figure 3. Mean concentrations (plus s.d.) of ifosfamide administered
alone (closed symbols, bars up) or in combination with pazopanib
(open symbols, bars down) during 3 consecutive bolus infusion days.
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Figure 4. Median plasma pazopanib concentration time profile (dose
escalation, in patients with continuously given ifosfamide).
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interaction was found (Plummer et al, 2013). Currently, extensive
PK analysis did not show an impact of pazopanib on serum levels
of ifosfamide or its metabolites.
In contrast, pazopanib exposure was clearly lowered by
concurrent infusion of ifosfamide. This effect of ifosfamide on
pazopanib levels yielded in similar pazopanib concentrations at the
end of the ifosfamide infusion, regardless of the dose of pazopanib
given. A potential underlying mechanism might be ifosfamide’s
inductive effects on CYP3A (Boddy et al, 1995) for which
pazopanib, in addition to being a weak inhibitor, is also a substrate
(Goh et al, 2010). If the induction of CYP3A by ifosfamide is
indeed the cause of the decreased pazopanib exposure, this could
imply that other drugs able to induce CYP3A should be avoided
during pazopanib therapy but this warrants further exploration.
Yet, this PK interaction does not explain the striking difference
in tolerability between the CIV and BIV schedule. In a study in
patients with soft tissue sarcoma, BIV and CIV administrations of
ifosfamide were compared demonstrating CIV to be slightly less
toxic in terms of a lower rate of treatment discontinuation due to
toxicity and a lower incidence of grade 3–4 dyspnoe and infection.
However, CIV induced a higher incidence of grade 3–4 anaemia
and grade 2–3 nausea than BIV ifosfamide (Lorigan et al, 2007).
The higher incidences of grade 3–4 neutropenia in the CIV
schedule (88%; 23 out of 26 patients) compared with the BIV (48%;
13 out of 27 patients) observed in this study were in contrast with
the study by Lorigan et al (2007) in which comparable incidences
in CIV- and BIV-treated patients for grade 3–4 neutropenia
incidence (62.7% vs 60.0%) were found. This strongly suggests that
the potentiating effect of pazopanib on the occurrence of
neutropenia depends on the chosen infusion schedule. Auto-
induction of ifosfamide is 52% higher during bolus infusion as
compared with continuous infusion (Kerbusch et al, 2001) and as a
result higher concentrations of ifosfamide are generated. Accord-
ingly, the AUC0–72 of ifosfamide in our trial was indeed higher
during bolus infusions as compared with the continuous infusion
(3149 mg*hml l vs 2234mg*hml l, respectively).
Three cytokines known to reflect biological effects from
VEGFR-TKIs showed alterations in PlGF, VEGF-A and sVEGFR
levels following exposure to pazopanib consistent with inhibition
of VEGFR2 activity (Sleijfer et al, 2012). Ifosfamide did not nullify
these pazopanib-induced biological effects, so ifosfamide does not
hinder pazopanib to exert biological effects despite its lowering
effects on pazopanib-levels.
This study shows that the upper boundary of safe dosing is, at
least, 1000mg per day pazopanib with CIV ifosfamide 9 gm 2.
Like the single-agent pazopanib dose-finding study, the tolerable
dose is higher than the currently approved dose, chosen on the
basis of PK parameters and analyses of biological activity (Hurwitz
et al, 2009). On the basis of the facts that the exposure to
pazopanib during ifosfamide is comparable in patients using
1000mg per day and 800mg per day after 48 h (Figure 4) and that
the pharmacodynamic parameters showed that the short period of
lower pazopanib levels using 800mg compared with 1000mg
pazopanib did not have any effects on the pazopanib-induced
biological effects, both in line with findings from the phase I
trial on pazopanib monotherapy (Hurwitz et al, 2009), we
recommend as dose for further studies 800mg pazopanib and
CIV ifosfamide 9 gm 2.
Importantly, this is the first phase I study to apply the 3þ 3þ 3
design. This pre-planned design for combination phase I trials
aims to eliminate chances of falsely halting dose escalation, based
on a high a priori chance of developing a DLT of one of the drugs
(Hamberg et al, 2010b). In the CIV arm, two out of the first six
patients at the 1000mg pazopanib dose level experienced a DLT.
According to the conventional 3þ 3 design, this would have been
interpreted as toxicity exceeding MTD. However, no DLTs were
encountered in the other nine patients enrolled in this dose level.
This strongly underscores the clinical applicability of this
3þ 3þ 3-approach in establishing the tolerability of drug
combinations.
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Figure 5. Pazopanib AUC administered as single agent (day 21,
cycle 1) vs combined administration with continuous ifosfamide
(day 3, cycle 2) in the dose expansion phase.
Table 3. Biomarkers in the dose escalation cohorts (baseline normalised to 1)
Ifosfamide
schedule Biomarker Pazopanib dose Baseline
After 7 days pazopanib
but prior to first ifosfamide
Prior to second
ifosfamide
CIV PlGF 400 1 1.75 1.35
800 1 6.87 8.46
1000 1 7.13 4.39
VEGF-A 400 1 1.08 0.54
800 1 5.26 5.72
1000 1 3.85 2.73
sVEGFR2 400 1 0.89 0.88
800 1 0.77 0.70
1000 1 0.76 0.69
BIV PlGF 200 1 1.81 1.75
400 1 2.40 3.24
VEGF-A 200 1 1.72 3.12
400 1 1.96 2.20
sVEGFR-2 200 1 0.89 0.81
400 1 0.79 0.77
Abbreviations: BIV¼bolus intravenous infusion; CIV¼ continuous intravenous infusion; PlGF¼placental-derived growth factor; sVEGFR2¼ soluble VEGFR2; VEGF-A¼ vascular endothelial
growth factor-A.
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In conclusion, this study has clearly demonstrated that
tolerability of pazopanib and ifosfamide is dependent on the
infusion schedule. An evident explanation for the observed
differences is not readily available. Furthermore, ifosfamide
appeared to lower pazopanib levels, but despite the lower levels
of pazopanib, it still exerted biological activity. In addition, this
study stresses the importance of the 3þ 3þ 3 design for exploring
drug combinations in phase I studies when one of the agents is
known to induce high rates of toxicity. Last, based upon our data
the dose recommended for pazopanib when combined with CIV
ifosfamide 9 gm 2 is 800mg, while a combination with bolus
ifosfamide is not feasible. Further studies on the combination of
pazopanib and ifosfamide are currently being designed.
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